Bis zu 90% sparen! Kostenloser Depotgebühren-Check
030-275 77 6400
DAX-0,17 % EUR/USD+0,42 % Gold-0,13 % Öl (Brent)-1,19 %

X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences

Nachrichtenquelle: Business Wire (engl.)
17.09.2019, 14:30  |  136   |   |   

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team is scheduled to conduct one-on-one meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, and to present and conduct one-on-one meetings at the 2019 Cantor Global Healthcare Conference.

Details related to the team’s participation are as follows:

Conference:

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

Location:

New York, NY

Date:

September 23rd

 

Conference:

2019 Cantor Global Healthcare Conference

Location:

New York, NY

Presentation Date & Time:

October 2nd at 4:10 pm EDT

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström’s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria. For more information, please visit www.x4pharma.com.

Diesen Artikel teilen
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
WHI


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel